About dabigatran
Direct thrombin inhibitor anticoagulant
Used for
- Preventing stroke and systemic embolism in nonvalvular atrial fibrillation
- Treating deep vein thrombosis and pulmonary embolism
- Preventing recurrent venous blood clots
- Preventing blood clots after hip replacement surgery
Usual adult dose
Usually 150 mg twice daily for atrial fibrillation or treatment and prevention of venous clots; lower doses may be prescribed for specific risks or conditions. Hip replacement: usually 110 mg initially, then 220 mg once daily.
Usual dose in children
For children aged 8 years and older, dosing is based on weight and the specific clotting condition; specialist supervision is required.
Common side effects
- Bleeding or bruising
- Indigestion or stomach discomfort
- Nausea
- Anemia
Important warnings
- Can cause serious or fatal bleeding
- Do not stop suddenly without medical direction; clot risk may increase
- Kidney function affects dosing and suitability
- Spinal procedures can rarely cause serious bleeding around the spine
Pregnancy
Generally avoided during pregnancy because of bleeding risks; evidence is limited.
Breastfeeding
Breastfeeding is generally not recommended during treatment because it is unknown whether dabigatran enters breast milk.
Interactions
- Other anticoagulants or antiplatelet medicines increase bleeding risk
- NSAIDs such as ibuprofen can increase bleeding risk
- Rifampicin can reduce dabigatran effects
- Some P-glycoprotein inhibitors can raise dabigatran levels
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.